[HTML][HTML] Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Abstract Background Budget impact analyses (BIAs) are an essential part of a
comprehensive economic assessment of a health care intervention and are increasingly …
comprehensive economic assessment of a health care intervention and are increasingly …
Budget impact analysis of medicines: updated systematic review and implications
DR Faleiros, J Álvares, AM Almeida… - Expert review of …, 2016 - Taylor & Francis
This evaluation determines whether published studies to date meet the key characteristics
identified for budget impact analyses (BIA) for medicines, accomplished through a …
identified for budget impact analyses (BIA) for medicines, accomplished through a …
Budget-impact analyses: a critical review of published studies
E Orlewska, L Gulácsi - Pharmacoeconomics, 2009 - Springer
This article reviews budget-impact analyses (BIAs) published to date in peer-reviewed bio-
medical journals with reference to current best practice, and discusses where future …
medical journals with reference to current best practice, and discusses where future …
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2–positive breast cancer
NL Liberato, M Marchetti, G Barosi - Journal of Clinical Oncology, 2007 - ascopubs.org
Purpose To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in
women with high-risk human epidermal growth factor receptor 2 (HER2)–positive early …
women with high-risk human epidermal growth factor receptor 2 (HER2)–positive early …
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
E Galve-Calvo, E González-Haba… - ClinicoEconomics …, 2018 - Taylor & Francis
Purpose The aim of this study was to evaluate the cost-effectiveness of ribociclib compared
to palbociclib, both in combination with letrozole, in the first-line treatment of …
to palbociclib, both in combination with letrozole, in the first-line treatment of …
The economic burden of metastatic breast cancer: a systematic review of literature from developed countries
TS Foster, JD Miller, ME Boye, MB Blieden… - Cancer treatment …, 2011 - Elsevier
OBJECTIVE: Breast cancer, the most common malignant cancer among women in Western
countries, has poor prognosis following metastasis. New therapies potentially extend …
countries, has poor prognosis following metastasis. New therapies potentially extend …
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
S Jang, YK Chae, T Haddad, NS Majhail - Breast cancer research and …, 2010 - Springer
To determine whether authors conducting economic analyses of aromatase inhibitors in
breast cancer are less likely to reach unfavorable conclusions if the economic study is …
breast cancer are less likely to reach unfavorable conclusions if the economic study is …
[HTML][HTML] Second-and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of …
G Ferretti, E Bria, D Giannarelli, A Felici… - British journal of …, 2006 - nature.com
The purpose of this study was to estimate in all randomised trials the relative risk of overall
response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS) …
response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS) …
Structural uncertainty of Markov models for advanced breast cancer: a simulation study of lapatinib
QA Le - Medical Decision Making, 2016 - journals.sagepub.com
Objective. To examine the impact of structural uncertainty of Markov models in modeling cost-
effectiveness for the treatment of advanced breast cancer (ABC). Methods. Four common …
effectiveness for the treatment of advanced breast cancer (ABC). Methods. Four common …
[HTML][HTML] Budget impact analysis of breast cancer medications: a systematic review
G Mohammadnezhad, M Sattarpour… - Journal of Pharmaceutical …, 2022 - Springer
Background Breast cancer (BC) is the most common cancer globally among women, with
2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both …
2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both …